Healthcare – Red Wave Press https://redwave.press We need more than a red wave. We need a red tsunami. Thu, 14 Nov 2024 21:33:53 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.2 https://redwave.press/wp-content/uploads/2024/09/cropped-Favicon-32x32.png Healthcare – Red Wave Press https://redwave.press 32 32 MAGA, Meet MAHA: RFK Jr. Tapped to Overhaul Healthcare, Fitness, and Big Pharma as Trump’s HHS Secretary https://redwave.press/maga-meet-maha-rfk-jr-tapped-to-overhaul-healthcare-fitness-and-big-pharma-as-trumps-hhs-secretary/ https://redwave.press/maga-meet-maha-rfk-jr-tapped-to-overhaul-healthcare-fitness-and-big-pharma-as-trumps-hhs-secretary/#respond Thu, 14 Nov 2024 21:33:53 +0000 https://redwave.press/maga-meet-maha-rfk-jr-tapped-to-overhaul-healthcare-fitness-and-big-pharma-as-trumps-hhs-secretary/ President Donald Trump had been expected to appoint Robert F. Kennedy, Jr, to a role in his administration that will oversea healthcare in some form. But instead of being a “czar” or advisor, Trump plugged RFK Jr right into the mix as Secretary of the Department of Health and Human Services.

According to his post on Truth Social:

I am thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of Health and Human Services (HHS). For too long, Americans have been crushed by the industrial food complex and drug companies who have engaged in deception, misinformation, and disinformation when it comes to Public Health. The Safety and Health of all Americans is the most important role of any Administration, and HHS will play a big role in helping ensure that everybody will be protected from harmful chemicals, pollutants, pesticides, pharmaceutical products, and food additives that have contributed to the overwhelming Health Crisis in this Country. Mr. Kennedy will restore these Agencies to the traditions of Gold Standard Scientific Research, and beacons of Transparency, to end the Chronic Disease epidemic, and to Make America Great and Healthy Again!

HHS is huge. It has 13 operating divisions, including 10 agencies in the U.S. Public Health Service and three human services agencies. Included under RFK’s purview will be the CDC, the FDA, and the NIH.

In other words, RFK will now be empowered to completely reshape healthcare in the United States from just about every federal angle.

Reactions to the news were stunning:

This move is truly transformative. As Kennedy and Trump have both highlighted, this nation was once the envy of the world for both healthcare and fitness of its citizens. Today, we’re the laughingstock. Kennedy is poised to truly Make America Healthy Again.

]]>
https://redwave.press/maga-meet-maha-rfk-jr-tapped-to-overhaul-healthcare-fitness-and-big-pharma-as-trumps-hhs-secretary/feed/ 0 228700
The Dangers of Statins https://redwave.press/the-dangers-of-statins/ https://redwave.press/the-dangers-of-statins/#respond Fri, 18 Oct 2024 05:59:05 +0000 https://redwave.press/the-dangers-of-statins/
  • One of the biggest misconceptions is that cholesterol causes heart disease and that statins, which lower cholesterol, prevent it. Not only is this untrue, but the highly profitable statins are also among the most harmful pharmaceuticals available (and share many eerie parallels to the COVID vaccines)
  • Despite growing evidence that lowering cholesterol does not reduce heart disease, the medical industry continues to push statins. Studies have shown that the benefits of statins are minimal, with data manipulated to exaggerate their effectiveness
  • Statins are aggressively promoted, not because of their efficacy, but due to financial interests in the pharmaceutical industry. Guidelines on cholesterol and statins are often created by experts who have conflicts of interest. Many doctors and patients are penalized for not adhering to these guidelines
  • Statins cause significant harm, with side effects like muscle pain, cognitive issues, and even life-threatening conditions such as diabetes and liver dysfunction. Despite widespread patient reports of these injuries, the medical community often dismisses them, attributing them to a “nocebo effect” or imagining the problem
  • (Mercola)—The more I study science, and particularly medicine, the more I come to see how often fundamental facts end up being changed so that a profitable industry can be created. Recently I showed how this happened with blood pressure, as rather than causing arterial damage, high blood pressure is a response to arterial damage that ensures damaged arteries can still bring blood to the tissues and, in turn, rather than helping patients, aggressively lowering blood pressure can be quite harmful.

    In this article, I will look at the other half of the coin, the Great Cholesterol Scam — something that harms so many Americans it was recently discussed by Comedian Jimmy Dore.

    Cholesterol and Heart Disease

    Frequently, when an industry harms many people, it will create a scapegoat to get out of trouble. Once this happens, a variety of other sectors will jump on the bandwagon and create an unshakable societal dogma.

    For example, the health of a population (or if they are being poisoned by environmental toxins) determines how easily an infectious disease can sweep through a population and who is susceptible to it, but reframing infectious diseases as a “deficiency of vaccines” it both takes the (costly) onus off the industries to clean up the society and simultaneously allows them to get rich promoting the pharmaceutical products that “manage” each epidemic and the even larger epidemic of chronic diseases caused by those vaccines (discussed in detail here).

    Note: The major decline in infectious illness that is credited to vaccines actually was a result of improved public sanitation, and when the data is examined (e.g., for smallpox) those early vaccination campaigns made things worse not better.

    In the 1960s and 1970s, a debate emerged over what caused heart disease. On one side, John Yudkin1 effectively argued that the sugar being added to our food by the processed food industry was the chief culprit. On the other side, Ancel Keys2 (who attacked Yudkin’s work) argued that it was due to saturated fat and cholesterol.

    Note: Leaders in the field of natural medicine, like Dr. Mercola, have made a strong case this spike came from the mass adoption of seed oils (which thanks to our unprecedented political climate is at last being discussed on the mainstream news). Likewise, some believe the advent of water chlorination was responsible for this increase.3

    Ancel Keys won, Yudkin’s work was largely dismissed, and Keys became nutritional dogma. A large part of Key’s victory was based on his study of seven countries (Italy, Greece, Former Yugoslavia, Netherlands, Finland, America, and Japan), which showed that as saturated fat consumption increased, heart disease increased in a linear fashion.

    However, what many don’t know (as this study is still frequently cited) is that this result was simply a product of the countries Keys chose (e.g., if Finland, Israel, Netherlands, Germany, Switzerland, France, and Sweden had been chosen, the opposite would have been found).

    Fortunately, it’s gradually become recognized that Keys did not accurately report his data. For example, recently an unpublished 56 month randomized study4 of 9,423 adults living in state mental hospitals or a nursing home (which made it possible to rigidly control their diets) was unearthed.

    This study, which Keys was the lead investigator of, found that replacing half of one’s animal (saturated) fats with seed oil (e.g., corn oil) lowered their cholesterol, but for every 30 points it dropped, their risk of death increased by 22% (which roughly translates to each 1% drop in cholesterol raising the risk of death by 1%).

    Note: The author who unearthed that study also discovered another (unpublished) study from the 1970s of 458 Australians, which found that5 replacing some of their saturated fat with seed oils increased their risk of dying by 17.6%.

    Likewise, recently, one of the most prestigious medical journals in the world published6 internal sugar industry documents. They showed7 the sugar industry had used bribes to make scientists place the blame for heart disease on fat so Yudkin’s work would not threaten the sugar industry. In turn, it is now generally accepted that Yudkin was right, but nonetheless, our medical guidelines are still largely based on Key’s work.

    However, despite a significant amount of data that now shows lowering cholesterol is not associated with a reduction in heart disease, the need to lower cholesterol is still a dogma within cardiology.8,9,10,11,12,13 For example, how many of you have heard of this 1986 study which was published in the Lancet14 which concluded:

    “During 10 years of follow-up from December 1, 1986, to October 1, 1996, a total of 642 participants died. Each 1 mmol/L increase in total cholesterol corresponded to a 15% decrease in mortality (risk ratio 0 to 85 [95% Cl 0·79 to 0·91]).”

    Statins Marketing

    One of the consistent patterns I’ve observed within medicine is that once a drug is identified that can “beneficially” change a number, medical practice guidelines will gradually shift to prioritizing treating that number and before long, rationales will be created that require more and more of the population to be subject to that regimen. Consider for example the history of the (immensely harmful) blood pressure guidelines:

    In the case of statins, prior to their discovery, it was difficult to reliably lower cholesterol, but once they hit the market, research rapidly emerged arguing for a greater and greater need to lower cholesterol, which in turn led to more and more people being placed on statins.

    As you would expect, similar increases also occurred within the USA. For example, in 2008 to 2009, 12% of Americans over 40 reported taking a statin, whereas in 2018 to 2019, that had increased to 35% of Americans.15 Given how much these drugs are used, it then raises a simple question — how much benefit do they produce?

    As it turns out, this is a remarkably difficult question to answer as the published studies use a variety of confusing metrics to obfuscate their data (which means that the published statin trials almost certainly inflate the benefits of statin therapy), and more importantly, virtually all of the data on statin therapy is kept by a “private” (industry-funded)16 research collaboration17 that consistently publishes glowing reviews of statins (and attacks anyone who claims otherwise)18 but simultaneously refuses to release their data to outside researchers,19 which has led to those researchers attempting to get this missing data from the drug regulators.20

    Note: As discussed in Dr. Malhotra’s interview below, this collaboration (which militantly insists less than 1% of statin users experience side effects) also created a test one could utilize to determine if one was genetically at risk for a statin injury — and in their marketing for the test said 29% of all statin users were likely to experience side effects (which they then removed once health activists publicized this hypocrisy).

    Nonetheless, when independent researchers looked at the published trials (which almost certainly inflated the benefit of statin therapy) they found21 that taking a statin daily for approximately 5 years resulted in you living, on average, 3 to 4 days longer. Sadder still, large trials have found22 this minuscule “benefit” is only seen in men. In short, most of the benefit from statins is from creative ways to rearrange data and causes of death, not any actual benefit.

    Note: This is very similar to Pfizer’s COVID vaccine trial23 which professed to be “95% effective” against COVID-19, but in reality only created a 0.8% reduction in minor symptoms of COVID (e.g., a sore throat) and a 0.037% reduction in severe symptoms of COVID (with “severe” never being defined by Pfizer).

    This in turn meant that you needed to vaccinate 119 people to prevent a minor (inconsequential) case of COVID-19, and 2711 to prevent a “severe” case of COVID-19.

    Worse still, a whistleblowers later revealed that these figures were greatly inflated as individuals in the (unblinded) vaccine group who developed COVID-19 like symptoms weren’t tested for COVID-19 and their vaccine injuries were never reported. Sadly, in most cases (e.g., the statin trials) we don’t have access to whistleblowers who can inform us of how unsafe and ineffective these drugs actually are.

    In circumstances like these where an unsafe and ineffective but highly lucrative drug must be sold, the next step is typically to pay everyone off to promote it. For example:24

    “The National Cholesterol Education Programme (NCEP) has been tasked by the National Institutes of Health to develop guidelines [everyone uses] for treating cholesterol levels. Excluding the chair (who was by law prohibited from having financial conflicts of interest), the other 8 members on average were on the payroll of 6 statin manufacturers.25

    In 2004, NCEP reviewed 5 large statin trials and recommended: ‘Aggressive LDL lowering for high-risk patients [primary prevention] with lifestyle changes and statins.’”

    In 2005 a Canadian division of the Cochrane Collaboration [who were not paid off] reviewed 5 large statin trials (3 were the same as NCEP’s, while the other 2 had also reached a positive conclusion for statin therapy). That independent assessment instead concluded:26 “Statins have not been shown to provide an overall health benefit in primary prevention trials.”

    Note: The primary reason no cure for COVID-19 was ever found was that the guideline panel for COVID-19 treatments was handpicked by Fauci27 and comprised of academics taking money from Remdesivir’s manufacturers. Not surprisingly, the panel always voted against recommending any of the non-patentable treatments for COVID-19, regardless of how much evidence there was for them.

    Likewise, the American College of Cardiology made a calculator28 to determine your risk of developing a heart attack or stroke in the next ten years based on your age, blood pressure, cholesterol level, and smoking status. In turn, I’ve lost track of how many doctors I saw proudly punch their patient’s numbers into it and then inform them that they were at high risk of a stroke or heart attack and urgently needed to start a statin.

    Given that almost everyone ended up being “high risk” I was not surprised to learn that in 2016, Kaiser completed an extensive study29 which determined that this calculator overestimated the rate of these events by 600%. Sadly, that has not at all deterred the use of this calculator (e.g., medical students are still tested on it for their board examinations).

    Note: One of the most unfair things about statins is that the health care system decided they are “essential” for your health, so doctors who don’t push them are financially penalized, and likewise patients who don’t take them are as well (e.g., through life insurance premiums).30

    So, despite the overwhelming evidence against their use, many physicians believe so deeply in the “profound” benefits of statins that they do things like periodically advocating for statins to be added to the drinking water supply.31

    In tandem, a cancel culture (reminiscent of what we saw with the COVID vaccines) has been created where anyone who challenges the use of Statins is immediately labeled as a “statin denier” accused of being a mass murderer and effectively canceled. Recently, a statin and COVID vaccine dissident, British Cardiologist Aseem Malhotra discussed the dirty parallels between these two industries on Joe Rogan:

    In addition to doctors being forced to follow these guidelines, patients often are too. Doctors often retaliate against patients who do not take statins (similar to how unvaccinated patients were reprehensibly denied essential medical care during COVID-19).

    Employers sometimes require cholesterol numbers to meet a certain threshold for employment (although they never did anything on the scale of the COVID-19 vaccine mandates placed on workers around America). Similarly, life insurance policies often penalize those with “unsafe” cholesterol numbers.

    Statin Injuries

    My primary issue with the statins is not the fact we waste billions each year on a useless therapy (approximately 25 billion per year in America alone).32 Rather, it’s the fact that they have a very high rate of injury. For example, the existing studies find between a 5% to 30% rate of injuries,33 and Dr. Malhotra, having gone through all the existing evidence estimates that 20% of statin users are injured by them.

    Likewise, statins are well known for having a high percentage of patients discontinue the drugs due to their side effects (e.g., one large study34 found 44.7% of older adults discontinue the drugs within a year of starting them, while another large study of adults of all ages found 47% discontinued within a year).35

    Statins in turn, are linked to a large number of complications36 that have been well-characterized (e.g., mechanistically) and described throughout the medical literature.37,38,39,40,41,42 One group of side effects are those perceived by the patient (which often make them want to stop using the medications). These include:

    • A high incidence of muscle pain43,44,45,46,47,48,49
    • Fatigue50,51 especially with exertion and exercise52
    • Muscle inflammation (whose cause remains “unknown”)53,54
    • Autoimmune muscle damage55,56,57,58
    • Psychiatric and neurologic issues such as depression, confusion, aggression, and memory loss59,60,61,62,63,64,65,66,67
    • Severe irritability68
    • Sleep issues69
    • Musculoskeletal disorders and injuries70,71
    • Sudden (sensorineural) hearing loss72
    • Gastrointestinal distress73

    The other group are those not overtly noticed by the patient. These include:

    • Type-2 diabetes,74,75,76,77,78 particularly in women79,80,81
    • Cancer82,83,84,85
    • Liver dysfunction and failure86,87
    • Cataracts88,89
    • ALS-like conditions and other central motor disorders (e.g., Parkinson’s disease and cerebellar ataxia)90,91,92,93,94
    • Lupus-like syndrome95
    • Susceptibility to herpes zoster (shingles)96,97,98
    • Interstitial cystitis99
    • Polymyalgia rheumatica100
    • Kidney injury101,102
    • Renal failure103

    From the start, I noticed statin patients often reported numbness, muscle pain, or cognitive issues after starting these drugs, which resolved once they stopped. When this was brought up with their doctors, the response was often hostile, with doctors insisting statins couldn’t be the cause, citing their own experience or claiming the patient needed to continue the medication to avoid a heart attack.

    In turn, as the years went by, I saw increasingly elaborate excuses being created to protect the statins from an ever-increasing awareness of their dangers. A common one was the “nocebo effect” — the idea that negative expectations caused the reported symptoms. For example, I lost count of how many doctors I knew who cited this 2016 study104 when patients stated they had been injured.

    The nocebo effect is the opposite of the placebo effect. While the placebo effect occurs when a person experiences positive outcomes from a treatment because they believe it will help, the nocebo effect happens when negative outcomes arise simply because a person expects harm from a treatment, even if the treatment itself is harmless or ineffective.

    This theory was used to dismiss patients’ experiences despite the fact that many were unaware of possible side effects until they occurred and then looked them up.

    If you take this story and replace “statin” with COVID-19 vaccines, you will see it is essentially what everyone has experienced over the last four years (e.g., I lost count of how many times vaccine myocarditis was diagnosed as “anxiety”).

    Note: Two adverse event reporting systems exist for adverse reactions to pharmaceuticals, MedWatch105 and FAERS.106 Like VAERS, they suffer from severe underreporting (it is estimated only 1% to 10% of adverse events are reported to them), but none the less, thousands of (ignored) reports can be found there of the common injuries which result from statins.107

    Conclusion

    Most pharmaceutical medications work by blocking the function of an enzyme within the body, which while an effective way to change physiology, is often incredibly detrimental as each enzyme within the body is there for a reason. Statins do just that (and at the time were a revolutionary approach since decades of research had not yielded a consistent way to lower cholesterol). Unfortunately, the enzyme they chose doesn’t just lower cholesterol.

    Sadly, however, since that was the only way to make statin’s “work,” the research community has largely ignored the consequences of eliminating all the other essential biomolecules that originate from mevalonate. For example, many of the characteristic side effects of statins can be addressed by simply supplementing with Coenzyme Q10 (an essential nutrient for the mitochondria, heart and muscles) — in fact Merck even patented a Statin-CoQ10 preparation.108

    However, acknowledging that would be akin to admitting statins are not “safe and effective” and it hence has never been done (a situation analogous to the fact many disabling childhood vaccine injuries could avoided if the vaccines were spaced out, yet those who proposed doing so are instead simply attacked for “not following the CDC’s schedule”).

    Worse still, the massive market for “lowering cholesterol” has suppressed all research into the actual causes of heart disease and as a result, despite spending 25 billion a year on statins,109 heart remains the top cause of death in America. This is an immense tragedy as the actual causes and treatments of heart disease have been known for decades, but still remain Forgotten Sides of Medicine.

    Author’s note: This is an abridged version of a longer article about the great cholesterol scam which goes into greater detail on the dangers of statins, the actual causes of heart disease, and the natural ways to safely heal the arterial system and prevent heart disease. That article and its additional references can be read here.

    A Note from Dr. Mercola About the Author

    A Midwestern Doctor (AMD) is a board-certified physician from the Midwest and a longtime reader of Mercola.com. I appreciate their exceptional insight on a wide range of topics and I’m grateful to share them. I also respect AMD’s desire to remain anonymous since AMD is still on the front lines treating patients. To find more of AMD’s work, be sure to check out The Forgotten Side of Medicine on Substack.

    See all references

    ]]>
    https://redwave.press/the-dangers-of-statins/feed/ 0 227301
    Election Year Medicare Move Costs Taxpayers $21B Over Next 3 Years https://redwave.press/election-year-medicare-move-costs-taxpayers-21b-over-next-3-years/ https://redwave.press/election-year-medicare-move-costs-taxpayers-21b-over-next-3-years/#respond Mon, 07 Oct 2024 11:21:31 +0000 https://redwave.press/election-year-medicare-move-costs-taxpayers-21b-over-next-3-years/ (Shirleen Guerra, The Center Square)—The Congressional Budget Office has released an analysis of the Biden administration’s newly announced Medicare prescription drug premiums, estimating the new program could cost taxpayers more than $21 billion over three years if implemented.

    The analysis comes after House Ways and Means Committee Chairman Jason Smith, R-Mo., House Budget Committee Chairman Jodey Arrington, R-Texas, and Senate Budget Committee Ranking Member Chuck Grassley, R-Iowa, sent a letter to Director Phillip Swagel of the CBO questioning the budgetary impact of this new demonstration program.

    A release from Swagel’s department said the increase in federal spending would range from $10 billion to $20 billion in 2025 compared to earlier projections.

    “As predicted, the Biden-Harris Inflation Reduction Act not only quelled investment for new cures, but caused Medicare prescription drug plan premiums to skyrocket, and Democrats are scrambling to cover it up before the election,” Arrington said in a press release. “In July, the Biden-Harris CMS scrambled to create a new federal program that will send billions of tax dollars to large health insurance companies to cover up a massive flaw in their so-called Inflation Reduction Act.”

    The new average plan bid for a standard Part D coverage increases by 179% for 2025 partly due to an underestimation of federal attributions to the Part D changes, according to the analysis.

    Arrington continued, “Today, CBO confirmed that the administration’s election year Hail Mary will cost taxpayers an astounding $7 billion next year alone, and $21 billion over the planned three-year demo, adding to the more than $2 trillion in Biden-Harris executive spending.”

    These plans typically expect monthly reinsurance, which means Medicare payments cover part of the costs of prescription drugs when the catastrophic threshold is reached.

    Almost 60% of Part D enrollees are through Medicare Advantage plans and receive coverage through MA-PD plans. The rest are covered through what’s known as stand-alone prescription drug plans.

    CBO expects the following changes for prescription drug plans in 2025:

    • A $15 reduction for monthly PDPs. This would cost a total of $2.9 billion in federal funding.
    • Increases in PDPs will be capped at $35 in 2024 and 2025, totaling $1.8 billion in federal funding.
    • Risk corridor subsidies will increase for PDPs that have more than 2.5% of bids in 2025, resulting in $250 million of federal funding.

    The budget office said the changes to temporary subsidies, combined with risk corridors, will increase federal spending by $5 billion in 2025, with $2 billion in net spending interest until 2034.

    Policies included in the $891 billion Inflation Reduction Act of 2022 have changed the Medicare Part D prescription drug benefit that was originally estimated to be $30 million over 10 years beginning in 2025.

    This resulted in the sponsors of the Medicare prescription drug plan increasing plan bids and base beneficiary premiums for 2025 while reducing the number of plans that would be available to seniors in 2025.

    “When Democrats unilaterally enacted major changes to Medicare two years ago, they set seniors up for new expenses and fewer options,” Grassley said in a release. “This nonpartisan CBO analysis confirms CMS’s cost-shifting plan is a dishonest election year gimmick to cover up those consequences.”

    CMS is an acronym for the Centers for Medicare & Medicaid Services.

    The program would send federal money to large health insurance companies while falsely lowering the cost for seniors Part D premiums and potentially costing $7 billion in 2025, according to the analysis.

    Grassley continued, “Rather than coming to the table and legitimately addressing its partisan mistakes, the Biden-Harris administration threw taxpayer dollars at the problems it created, putting Americans on the hook for tens of billions more dollars.”

    The Centers for Medicare & Medicaid Services Administrator Chiquita Brooks-LaSure said in a release, “Today’s final guidance for the Medicare Drug Price Negotiation Program builds off the success of the first 10 negotiated drug prices and continues the Biden-Harris administration’s commitment to provide millions of people with Medicare affordable access to innovative therapies.”

    This is a contradiction from the reported number taxpayers will pay that was stated in the analysis.

    Brooks-LaSure continued, “While saving Medicare and taxpayers billions of dollars, the negotiated prices will also provide people with Medicare a better deal on some of Medicare’s costliest prescription drugs, promoting necessary competition in the market, and ensuring Medicare is strong today and into the future.”

    The temporary subsidies, announced in July, affect both those enrolled and the federal payments to Plan D premiums in 2025, 2026 and 2027, though certain policies have yet to be announced for 2026-27, meaning no budgetary estimation for both years.

    The budget office said it expects $100 million in 2025 from each organization that controls and collects payments from the government on behalf of Part D plans.

    Continuing that most of that would have been paid for by enrollees in the Part D program through premiums, “For that reason, the effect of CMS’s subsidies on plans’ revenues is much smaller than the federal cost. By providing larger federal subsidies to prescription drug plans, the federal payments to Part D plans effectively cover costs that would have been borne by Part D enrollees.”

    ]]>
    https://redwave.press/election-year-medicare-move-costs-taxpayers-21b-over-next-3-years/feed/ 0 226762